Supplementary Figure 5 from Development of Novel ADCs: Conjugation of Tubulysin Analogues to Trastuzumab Monitored by Dual Radiolabeling Article Swipe

PDF

Ruth Cohen , Daniëlle J. Vugts , Gerard W.M. Visser , Marijke Stigter‐van Walsum , Marije Bolijn , M. Spiga , Paolo Lazzari , Sreejith Shankar , Monica Sani , Matteo Zanda , Guus A.M.S. van Dongen ·

YOU? · · 2023 · Open Access · · DOI: https://doi.org/10.1158/0008-5472.22404134

In vivo efficacy of TUB-OMOM-trastuzumab JIMT-tumor bearing mice. The effect after a single i.p. injection of NaCl (control, red line), trastuzumab (15 mg/kg, green line),15 mg/kg TUB-OMOM-trastuzumab (blue line), 30 mg/kg TUB-OMOM-trastuzumab (purple line) 60 mg/kg TUB-OMOM-trastuzumab (orange line) or trastuzumab emtansine (T-DM1; 15 mg/kg, black line). Error bars are not shown, due to large differences in tumor growth in time.

Related Topics

Concepts

Trastuzumab Chemistry Pharmacology Internal medicine Medicine Cancer Breast cancer

Metadata

Type: preprint
Language: en
Landing Page: https://doi.org/10.1158/0008-5472.22404134
PDF: https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_5_from_Development_of_Novel_ADCs_Conjugation_of_Tubulysin_Analogues_to_Trastuzumab_Monitored_by_Dual_Radiolabeling/22404134/1/files/39849947.pdf
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4361874239

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4361874239

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/0008-5472.22404134

Digital Object Identifier
Title: Supplementary Figure 5 from Development of Novel ADCs: Conjugation of Tubulysin Analogues to Trastuzumab Monitored by Dual Radiolabeling

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2023

Year of publication
Publication date: 2023-03-30

Full publication date if available
Authors: Ruth Cohen, Daniëlle J. Vugts, Gerard W.M. Visser, Marijke Stigter‐van Walsum, Marije Bolijn, M. Spiga, Paolo Lazzari, Sreejith Shankar, Monica Sani, Matteo Zanda, Guus A.M.S. van Dongen

List of authors in order
Landing page: https://doi.org/10.1158/0008-5472.22404134

Publisher landing page
PDF URL: https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_5_from_Development_of_Novel_ADCs_Conjugation_of_Tubulysin_Analogues_to_Trastuzumab_Monitored_by_Dual_Radiolabeling/22404134/1/files/39849947.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_5_from_Development_of_Novel_ADCs_Conjugation_of_Tubulysin_Analogues_to_Trastuzumab_Monitored_by_Dual_Radiolabeling/22404134/1/files/39849947.pdf

Direct OA link when available
Concepts: Trastuzumab, Chemistry, Pharmacology, Internal medicine, Medicine, Cancer, Breast cancer

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4361874239
doi	https://doi.org/10.1158/0008-5472.22404134
ids.doi	https://doi.org/10.1158/0008-5472.22404134
ids.openalex	https://openalex.org/W4361874239
fwci	0.0
type	preprint
title	Supplementary Figure 5 from Development of Novel ADCs: Conjugation of Tubulysin Analogues to Trastuzumab Monitored by Dual Radiolabeling
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T11395
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9866999983787537
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2741
topics[0].subfield.display_name	Radiology, Nuclear Medicine and Imaging
topics[0].display_name	Radiopharmaceutical Chemistry and Applications
topics[1].id	https://openalex.org/T10755
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9864000082015991
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2730
topics[1].subfield.display_name	Oncology
topics[1].display_name	HER2/EGFR in Cancer Research
topics[2].id	https://openalex.org/T10417
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9402999877929688
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2740
topics[2].subfield.display_name	Pulmonary and Respiratory Medicine
topics[2].display_name	Lung Cancer Treatments and Mutations
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2779786085
concepts[0].level	4
concepts[0].score	0.9654768705368042
concepts[0].wikidata	https://www.wikidata.org/wiki/Q412616
concepts[0].display_name	Trastuzumab
concepts[1].id	https://openalex.org/C185592680
concepts[1].level	0
concepts[1].score	0.4637470841407776
concepts[1].wikidata	https://www.wikidata.org/wiki/Q2329
concepts[1].display_name	Chemistry
concepts[2].id	https://openalex.org/C98274493
concepts[2].level	1
concepts[2].score	0.34003520011901855
concepts[2].wikidata	https://www.wikidata.org/wiki/Q128406
concepts[2].display_name	Pharmacology
concepts[3].id	https://openalex.org/C126322002
concepts[3].level	1
concepts[3].score	0.30308765172958374
concepts[3].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[3].display_name	Internal medicine
concepts[4].id	https://openalex.org/C71924100
concepts[4].level	0
concepts[4].score	0.25876641273498535
concepts[4].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[4].display_name	Medicine
concepts[5].id	https://openalex.org/C121608353
concepts[5].level	2
concepts[5].score	0.17064493894577026
concepts[5].wikidata	https://www.wikidata.org/wiki/Q12078
concepts[5].display_name	Cancer
concepts[6].id	https://openalex.org/C530470458
concepts[6].level	3
concepts[6].score	0.14925867319107056
concepts[6].wikidata	https://www.wikidata.org/wiki/Q128581
concepts[6].display_name	Breast cancer
keywords[0].id	https://openalex.org/keywords/trastuzumab
keywords[0].score	0.9654768705368042
keywords[0].display_name	Trastuzumab
keywords[1].id	https://openalex.org/keywords/chemistry
keywords[1].score	0.4637470841407776
keywords[1].display_name	Chemistry
keywords[2].id	https://openalex.org/keywords/pharmacology
keywords[2].score	0.34003520011901855
keywords[2].display_name	Pharmacology
keywords[3].id	https://openalex.org/keywords/internal-medicine
keywords[3].score	0.30308765172958374
keywords[3].display_name	Internal medicine
keywords[4].id	https://openalex.org/keywords/medicine
keywords[4].score	0.25876641273498535
keywords[4].display_name	Medicine
keywords[5].id	https://openalex.org/keywords/cancer
keywords[5].score	0.17064493894577026
keywords[5].display_name	Cancer
keywords[6].id	https://openalex.org/keywords/breast-cancer
keywords[6].score	0.14925867319107056
keywords[6].display_name	Breast cancer
language	en
locations[0].id	doi:10.1158/0008-5472.22404134
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_5_from_Development_of_Novel_ADCs_Conjugation_of_Tubulysin_Analogues_to_Trastuzumab_Monitored_by_Dual_Radiolabeling/22404134/1/files/39849947.pdf
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/0008-5472.22404134
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5112904686
authorships[0].author.orcid
authorships[0].author.display_name	Ruth Cohen
authorships[0].author_position	first
authorships[0].raw_author_name	Ruth Cohen
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5004839794
authorships[1].author.orcid	https://orcid.org/0000-0001-7068-8152
authorships[1].author.display_name	Daniëlle J. Vugts
authorships[1].author_position	middle
authorships[1].raw_author_name	Danielle J. Vugts
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5110258957
authorships[2].author.orcid
authorships[2].author.display_name	Gerard W.M. Visser
authorships[2].author_position	middle
authorships[2].raw_author_name	Gerard W.M. Visser
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5069697405
authorships[3].author.orcid	https://orcid.org/0000-0003-3972-3460
authorships[3].author.display_name	Marijke Stigter‐van Walsum
authorships[3].author_position	middle
authorships[3].raw_author_name	Marijke Stigter-van Walsum
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5005250110
authorships[4].author.orcid
authorships[4].author.display_name	Marije Bolijn
authorships[4].author_position	middle
authorships[4].raw_author_name	Marije Bolijn
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5001908272
authorships[5].author.orcid	https://orcid.org/0000-0002-9348-6331
authorships[5].author.display_name	M. Spiga
authorships[5].author_position	middle
authorships[5].raw_author_name	Marco Spiga
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5106629776
authorships[6].author.orcid
authorships[6].author.display_name	Paolo Lazzari
authorships[6].author_position	middle
authorships[6].raw_author_name	Paolo Lazzari
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5068371168
authorships[7].author.orcid	https://orcid.org/0000-0002-1158-5935
authorships[7].author.display_name	Sreejith Shankar
authorships[7].author_position	middle
authorships[7].raw_author_name	Sreejith Shankar
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5108084270
authorships[8].author.orcid
authorships[8].author.display_name	Monica Sani
authorships[8].author_position	middle
authorships[8].raw_author_name	Monica Sani
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5040102137
authorships[9].author.orcid	https://orcid.org/0000-0002-8257-5232
authorships[9].author.display_name	Matteo Zanda
authorships[9].author_position	middle
authorships[9].raw_author_name	Matteo Zanda
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5110812163
authorships[10].author.orcid
authorships[10].author.display_name	Guus A.M.S. van Dongen
authorships[10].author_position	last
authorships[10].raw_author_name	Guus A.M.S. van Dongen
authorships[10].is_corresponding	False
has_content.pdf	True
has_content.grobid_xml	True
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_5_from_Development_of_Novel_ADCs_Conjugation_of_Tubulysin_Analogues_to_Trastuzumab_Monitored_by_Dual_Radiolabeling/22404134/1/files/39849947.pdf
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Supplementary Figure 5 from Development of Novel ADCs: Conjugation of Tubulysin Analogues to Trastuzumab Monitored by Dual Radiolabeling
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T11395
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9866999983787537
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2741
primary_topic.subfield.display_name	Radiology, Nuclear Medicine and Imaging
primary_topic.display_name	Radiopharmaceutical Chemistry and Applications
related_works	https://openalex.org/W1963781110, https://openalex.org/W2286231588, https://openalex.org/W4281790686, https://openalex.org/W2572049769, https://openalex.org/W2170852072, https://openalex.org/W2807206954, https://openalex.org/W2117497402, https://openalex.org/W4362561157, https://openalex.org/W2315143255, https://openalex.org/W2075966869
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/0008-5472.22404134
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_5_from_Development_of_Novel_ADCs_Conjugation_of_Tubulysin_Analogues_to_Trastuzumab_Monitored_by_Dual_Radiolabeling/22404134/1/files/39849947.pdf
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/0008-5472.22404134
primary_location.id	doi:10.1158/0008-5472.22404134
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_5_from_Development_of_Novel_ADCs_Conjugation_of_Tubulysin_Analogues_to_Trastuzumab_Monitored_by_Dual_Radiolabeling/22404134/1/files/39849947.pdf
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/0008-5472.22404134
publication_date	2023-03-30
publication_year	2023
referenced_works_count	0
abstract_inverted_index.a	11
abstract_inverted_index.15	43
abstract_inverted_index.30	29
abstract_inverted_index.60	34
abstract_inverted_index.in	56, 59
abstract_inverted_index.of	3, 15
abstract_inverted_index.or	39
abstract_inverted_index.to	53
abstract_inverted_index.(15	21
abstract_inverted_index.The	8
abstract_inverted_index.are	49
abstract_inverted_index.due	52
abstract_inverted_index.not	50
abstract_inverted_index.red	18
abstract_inverted_index.NaCl	16
abstract_inverted_index.bars	48
abstract_inverted_index.i.p.	13
abstract_inverted_index.vivo	1
abstract_inverted_index.(blue	27
abstract_inverted_index.Error	47
abstract_inverted_index.after	10
abstract_inverted_index.black	45
abstract_inverted_index.green	23
abstract_inverted_index.large	54
abstract_inverted_index.line)	33, 38
abstract_inverted_index.mg/kg	25, 30, 35
abstract_inverted_index.mice.	7
abstract_inverted_index.tumor	57
abstract_inverted_index.effect	9
abstract_inverted_index.growth	58
abstract_inverted_index.line),	19, 28
abstract_inverted_index.line).	46
abstract_inverted_index.mg/kg,	22, 44
abstract_inverted_index.shown,	51
abstract_inverted_index.single	12
abstract_inverted_index.(T-DM1;	42
abstract_inverted_index.(orange	37
abstract_inverted_index.(purple	32
abstract_inverted_index.bearing	6
abstract_inverted_index.efficacy	2
abstract_inverted_index.line),15	24
abstract_inverted_index.(control,	17
abstract_inverted_index.emtansine	41
abstract_inverted_index.injection	14
abstract_inverted_index.JIMT-tumor	5
abstract_inverted_index.<p>In	0
abstract_inverted_index.differences	55
abstract_inverted_index.trastuzumab	20, 40
abstract_inverted_index.time.</p>	60
abstract_inverted_index.TUB-OMOM-trastuzumab	4, 26, 31, 36
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	11
citation_normalized_percentile.value	0.06850702
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False